Carl P. Sherr & Co. LLC Sells 800 Shares of Zoetis Inc. (NYSE:ZTS)

Carl P. Sherr & Co. LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 11.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,183 shares of the company’s stock after selling 800 shares during the quarter. Carl P. Sherr & Co. LLC’s holdings in Zoetis were worth $1,220,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC increased its holdings in Zoetis by 7.4% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock valued at $16,308,000 after purchasing an additional 6,457 shares during the last quarter. Peak Financial Advisors LLC bought a new stake in Zoetis in the fourth quarter valued at about $2,776,000. BLB&B Advisors LLC increased its holdings in Zoetis by 1.9% in the third quarter. BLB&B Advisors LLC now owns 60,872 shares of the company’s stock valued at $10,591,000 after purchasing an additional 1,107 shares during the last quarter. Ronald Blue Trust Inc. increased its holdings in Zoetis by 5.4% in the third quarter. Ronald Blue Trust Inc. now owns 6,216 shares of the company’s stock valued at $1,070,000 after purchasing an additional 317 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its stake in Zoetis by 10.9% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock valued at $36,230,000 after acquiring an additional 17,976 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 2.2 %

NYSE ZTS traded up $3.25 during trading hours on Wednesday, hitting $153.02. 4,967,617 shares of the company traded hands, compared to its average volume of 3,610,045. The business’s 50-day moving average is $178.25 and its 200-day moving average is $180.59. Zoetis Inc. has a twelve month low of $148.48 and a twelve month high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The stock has a market capitalization of $69.99 billion, a price-to-earnings ratio of 30.18, a P/E/G ratio of 2.29 and a beta of 0.85.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same period last year, the company posted $1.15 earnings per share. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. Sell-side analysts anticipate that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.13%. Zoetis’s dividend payout ratio is 34.12%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Piper Sandler reissued an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday. Jefferies Financial Group reissued a “buy” rating and issued a $230.00 target price on shares of Zoetis in a research note on Tuesday, December 19th. Stifel Nicolaus decreased their target price on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. The Goldman Sachs Group boosted their target price on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $221.75.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $191.43, for a total value of $176,689.89. Following the sale, the executive vice president now owns 17,569 shares in the company, valued at $3,363,233.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 2,209 shares of company stock worth $408,453 over the last 90 days. Company insiders own 0.15% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.